Hexarelin vs Ipamorelin: Growth-Hormone Secretagogues Compared

Hexarelin and ipamorelin are both synthetic growth hormone secretagogues (GHS) that bind the GHS-R — the ghrelin receptor on pituitary somatotroph cells — and stimulate endogenous GH release ^[8]. Both are compounded peptides used off-label in wellness and anti-aging contexts, and neither is FDA-approved for any human indication. But the pharmacological similarity ends at the receptor. Hexarelin, a hexapeptide first studied in human volunteers in 1997 ^[1], is among the most potent synthetic GH-releasing peptides known — yet it is non-selective: at standard acute doses in humans it also significantly raises ACTH, cortisol, and prolactin ^[2][3], and its GH-releasing response attenuates substantially with continued twice-daily dosing over weeks ^[4]. Ipamorelin, a pentapeptide developed as a second-generation GHS, was deliberately engineered around those limitations: in preclinical models it releases GH with no significant cortisol or prolactin elevation even at doses more than 200-fold its GH-releasing threshold ^[6]. For the broader comparison that includes GHRH-pathway agents, see sermorelin vs. CJC-1295/ipamorelin. For ipamorelin's reported adverse effects, see ipamorelin side effects and safety evidence. This article focuses on the head-to-head pharmacological differences between hexarelin and ipamorelin — and what the evidence does and does not support.

Mechanism: a shared receptor, opposite selectivity profiles

Both hexarelin and ipamorelin belong to the growth hormone secretagogue (GHS) family — synthetic peptides that activate the GHS-R1a (ghrelin receptor) on anterior pituitary somatotrophs and at the hypothalamic level to stimulate GH secretion ^[8]. This receptor pathway is distinct from the GHRH receptor pathway used by sermorelin and CJC-1295: where GHRH analogs amplify the “go” signal from the hypothalamus, GHS peptides act partly as functional somatostatin antagonists, releasing the pituitary's brake on GH output ^[8]. Administering a GHS alongside a GHRH analog is theorized to produce synergistic GH release through independent inputs to the same somatotroph cell — the rationale behind the CJC-1295/ipamorelin combination protocol.

Hexarelin is a hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) first characterized pharmacologically in the early 1990s. It binds GHS-R1a with high affinity and produces robust, dose-dependent GH release in humans ^[1][2]. The problem is receptor promiscuity: hexarelin also activates pathways that drive ACTH and prolactin secretion, and at standard doses in human studies it significantly elevates both ^[2][3]. It also binds CD36 — a multifunctional glycoprotein expressed in cardiomyocytes — through a GHS-R-independent mechanism that produces direct cardiovascular effects ^[5].

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed with the explicit goal of retaining GHS-R potency while eliminating the cortisol and prolactin liability ^[6]. The structural change was successful in preclinical models: ipamorelin releases GH with a potency and efficacy comparable to GHRP-6 in both rodents and swine, but unlike GHRP-6 and GHRP-2 it does not raise ACTH or cortisol at any tested dose ^[6]. Whether this selectivity advantage fully persists in humans at clinically used doses has not been confirmed in a dedicated head-to-head endocrine study.

Hexarelin: human evidence for GH potency and non-selectivity

Hexarelin is better characterized in humans than most compounded GHS peptides, though its published evidence still falls well short of a pivotal clinical trial. Loche et al. (1997) conducted the first controlled human study: eight normal men aged 21–33 received hexarelin 2 μg/kg subcutaneously both in the morning and at sleep onset. Mean peak GH concentrations reached 58.2 ± 4.7 μg/L in the morning and 61.2 ± 4.3 μg/L at sleep onset — potent GH release by any measure. GH was cleared more slowly during sleep (t½ 64.9 ± 14.8 min vs 24.9 ± 1.4 min, P < 0.01), meaning the nocturnal AUC was significantly larger (1466 vs 903 μg·min/L, P < 0.001) ^[1].

The non-selectivity profile was quantified in two human studies. Arvat et al. (2001) compared ghrelin, hexarelin, and GHRH in seven normal young men at 1.0 μg/kg IV. Hexarelin produced a GH peak of 68.4 ± 14.7 μg/L and “significantly stimulates PRL, ACTH, and cortisol secretion” — the authors' own phrasing ^[2]. Frieboes et al. (2004) studied seven healthy volunteers receiving hexarelin 4 × 50 μg subcutaneously over the night: significant increases in GH and prolactin were observed across the total night, and significant increases in ACTH and cortisol during the first half of the night ^[3]. In both studies, hexarelin produced cortisol and ACTH elevation that is not seen with ipamorelin in preclinical data.

Ipamorelin: preclinical selectivity and human pharmacokinetics

Ipamorelin was introduced to the pharmacology literature by Raun et al. (1998), who conducted an extensive preclinical characterization in rats and swine. In conscious swine, ipamorelin produced GH release with an ED₅₀ of 2.3 nmol/kg and a maximum of 65 ng/ml plasma GH — comparable to GHRP-6. Critically, ipamorelin did not raise ACTH, cortisol, prolactin, FSH, LH, or TSH at any tested dose, whereas both GHRP-6 and GHRP-2 produced significant ACTH and cortisol elevation. The absence of cortisol effect was maintained at doses “more than 200-fold higher than the ED₅₀ for GH release” — the authors' exact language ^[6].

The only published human pharmacokinetic study for ipamorelin is Gobburu et al. (1999): a dose-escalation IV infusion trial in 40 healthy male volunteers (8 subjects per dose level, five infusion rates from 4.21 to 140.45 nmol/kg over 15 minutes). Ipamorelin showed dose-proportional pharmacokinetics with a short terminal half-life of 2 hours, a clearance of 0.078 L/h/kg, and a volume of distribution at steady-state of 0.22 L/kg. GH peaked at approximately 0.67 hours post-infusion across dose levels, consistent with a rapid and transient GH pulse from a short-acting GHS-R agonist ^[7]. This study did not report cortisol or prolactin levels; the selectivity claim for ipamorelin in humans therefore remains inferred from Raun et al.'s preclinical data, not directly confirmed in a human endocrine trial. For a full review of ipamorelin's reported adverse effects, see ipamorelin side effects and safety evidence.

Desensitization: hexarelin's GH response attenuates with continued dosing

One of the most clinically significant differences between hexarelin and ipamorelin is the evidence for GHS-R desensitization with hexarelin. Rahim and Shalet (1998) conducted a 16-week study in 12 healthy elderly individuals receiving twice-daily subcutaneous hexarelin. The mean GH area under the curve (AUC_GH) decreased significantly over the study: 19.1 ± 2.4 μg/L/h at week 0, 13.1 ± 2.3 at week 1, 12.3 ± 2.4 at week 4, and 10.5 ± 1.8 μg/L/h at week 16 (P = 0.0003) ^[4] — approximately a 45% attenuation. Importantly, the attenuation was partially reversible: four weeks after stopping hexarelin, AUC_GH rebounded to 19.4 ± 3.7 μg/L/h, not significantly different from baseline ^[4].

No equivalent long-term desensitization study exists for ipamorelin. The absence of published data is a data gap, not evidence of absence. However, hexarelin's documented GH-response attenuation — reaching clinical significance within weeks at standard twice-daily dosing — is a clear limitation not established for ipamorelin, and is one reason wellness protocols commonly favor ipamorelin over hexarelin for multi-week cycling.

Hexarelin's direct cardiac effects: the CD36 pathway

Beyond the GHS-R, hexarelin binds a second cardiac target. Bodart et al. (2002) identified CD36 — a multifunctional glycoprotein expressed in cardiomyocytes and microvascular endothelial cells — as the molecular mediator of hexarelin's cardiovascular effects. Using a radioactive photoactivatable derivative of hexarelin to label rat cardiac membranes, the team isolated and N-terminally sequenced a binding protein of molecular weight 84,000, confirming it as CD36. In isolated perfused rat hearts, hexarelin elicited dose-dependent increases in coronary perfusion pressure; this vasoconstriction was absent in hearts from CD36-null mice and from spontaneously hypertensive rats genetically deficient in CD36 ^[5].

The clinical relevance of hexarelin's CD36 binding in humans has not been established. CD36 is expressed in the human myocardium and plays roles in fatty acid transport and scavenger receptor function. Some preclinical research has explored hexarelin's CD36 pathway for potential cardioprotective applications, but the coronary vasoconstriction finding raises concern in populations with coronary artery disease or atherosclerosis, where CD36 is upregulated. Ipamorelin has not been reported to bind CD36; its cardiovascular interaction appears limited to GHS-R-mediated effects.

Head-to-head comparison

Regulatory status and WADA classification

Neither hexarelin nor ipamorelin has ever received FDA approval for any human indication. There is no NDA or IND on record for either compound in the United States, and both are available only as compounded preparations from 503A pharmacy compounders. The FDA has exercised enforcement discretion over various peptide compounders, and the legal compoundability of specific GHS peptides can shift; neither hexarelin nor ipamorelin benefits from the “prior-NDA” pathway that gives sermorelin a degree of regulatory footing (see sermorelin vs. CJC-1295/ipamorelin for that distinction).

For competitive athletes, both compounds are unambiguously prohibited. WADA places all growth hormone secretagogues — including hexarelin and ipamorelin — under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited both in- and out-of-competition. GHS peptides are detectable by mass spectrometry in urine and blood samples at WADA-accredited laboratories ^[8].

Body-composition and weight-loss claims: what the evidence supports

A PubMed search for hexarelin or ipamorelin combined with “weight loss,” “fat mass,” or “body composition randomized” returns no published RCT for either agent. For the ipamorelin evidence specifically, see our ipamorelin weight-loss evidence review. The body-composition rationale for both compounds rests on the upstream GH biology — GH promotes lipolysis and lean-mass preservation, and GH secretion declines with age and obesity — but plausibility is not evidence.

• Hexarelin: all published human studies measured GH peaks and acute hormonal endpoints, not fat mass or body weight ^[1][2][3]. The desensitization study by Rahim and Shalet measured AUC_GH over 16 weeks in elderly subjects and reported no body-composition data ^[4]. No hexarelin body-composition trial in any human population has been published.
• Ipamorelin: the only published human RCT (Beck et al. 2014, PMID 25331030) tested postoperative ileus in bowel-resection patients and had no body-composition or GH endpoint. There is no weight-loss or fat-mass RCT for ipamorelin.
• Mechanism does not equal outcome: GH elevation is a pharmacodynamic marker. Even in GH-deficient adults where recombinant GH therapy is approved and produces modest body-composition improvements, the effect size varies and depends on GH deficiency severity. Extrapolating from “this peptide raises GH” to “this peptide causes weight loss” requires a clinical trial that does not exist for either agent.
• Comparison with approved obesity pharmacotherapy: FDA-approved GLP-1 and GIP/GLP-1 agonists (semaglutide, tirzepatide) are supported by large phase 3 randomized trials showing double-digit total body weight reduction as a primary endpoint. Hexarelin and ipamorelin offer no equivalent evidence base and are not evidence-based substitutes.